A new class of antigen-specific killer cells [see comments] NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A new class of antigen-specific killer cells [see comments]

Nat Biotechnol. 1997 Jan;15(1):46-51. Unique Identifier : AIDSLINE MED/97187652
Yang AG; Chen SY; Department of Cancer Biology, Bowman Gray School of Medicine, Wake; Forest University, Winston-Salem, NC 27157, USA.

Abstract: A new class of antigen-specific killer cells that combines the features of antibody-mediated and cell-mediated immunity was designed. The principle and feasibility of this strategy are illustrated by creating an antigen-specific killer cell to produce and secrete targeted antibody-toxin molecules that recognize and kill human immunodeficiency virus (HIV)-1-infected cells. The transduced lymphocytes, which were able to produce and secrete the targeted toxin proteins, remained viable due to the lack of the target antigen on the cell surface. These transduced cells were found to have selective and potent cytotoxicity to the HIV-infected cells. This approach combines the specificity of antibodies, extreme potency of toxins, and effector-cell properties of T-cells to generate a new class of potent antigen-specific killer cells, which may have broad applications for the treatment of viral infection and other diseases. This study demonstrates the principle that mammalian cells can be genetically modified to produce targeted toxins, indicating that in vivo production of targeted toxins can be achieved to locally or systematically destroy targeted cells.
Keywords: *Antibodies, Monoclonal/GENETICS *HIV Envelope Protein gp120/IMMUNOLOGY *Immunotoxins/GENETICS *Recombinant Fusion Proteins/BIOSYNTHESIS *T-Lymphocytes/IMMUNOLOGYKWDantibodies,monoclonal/geneticsKWDhivenvelopeproteingp120/immunologyKWDimmunotoxins/geneticsKWDrecombinantfusionproteins/biosynthesisKWDt-lymphocytes/immunology
Comment in: Nat Biotechnol 1997 Jan;15(1 ):18-9
970630
M9761172

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .